Cognition Therapeutics, a Phase 2 biotech developing small molecule therapies for Alzheimer's and other CNS diseases, filed on Monday with the SEC to raise up to $50 million in an initial public offering.
Cognition Therapeutics is developing small molecule therapies for age-related degenerative diseases and disorders of the CNS and the retina, with an initial aim to leverage its expertise in the sigma-2 receptor. Its lead program, CT1812, is a small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. CT1812 is currently in enrolling patients in a Phase 2 trial in patients with mild-to-moderate Alzheimer's disease.
The Purchase, NY-based company was founded in 2007 and plans to list on the Nasdaq under the symbol CGTX. Cognition Therapeutics filed confidentially on May 7, 2021. B. Riley Securities is the sole bookrunner on the deal. No pricing terms were disclosed.
